When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CELG - MorphoSys earns $3M milestone from I-Mab on start of multiple myeloma study
Celgene Corporation
The first patient has been dosed in a Phase 3 clinical trial in Taiwan evaluating MorphoSys AG's (MOR) CD38-targeting antibody TJ202/MOR202, combined with Celgene's (CELG) Revlimid (lenalidomide), in patients with relapsed/refractory multiple myeloma.
More news on: MorphoSys AG, Celgene Corporation, Healthcare stocks news,